Oral Transmucosal Cannabidiol Oil Formulation as Part of a Multimodal Analgesic Regimen: Effects on Pain Relief and Quality of Life Improvement in Dogs Affected by Spontaneous Osteoarthritis

The aim of this study was to evaluate the efficacy of oral transmucosal (OTM) cannabidiol (CBD), in addition to a multimodal pharmacological treatment for chronic osteoarthritis-related pain in dogs. Twenty-one dogs were randomly divided into two groups: in group CBD (n = 9), OTM CBD (2 mg kg−1 ever...

Full description

Saved in:
Bibliographic Details
Published in:Animals (Basel) 2020-09, Vol.10 (9), p.1505
Main Authors: Brioschi, Federica Alessandra, Di Cesare, Federica, Gioeni, Daniela, Rabbogliatti, Vanessa, Ferrari, Francesco, D’Urso, Elisa Silvia, Amari, Martina, Ravasio, Giuliano
Format: Article
Language:English
Subjects:
Amitriptyline
Analgesics
Anti-inflammatory agents
Arthritis
Biomedical materials
Canine Brief Pain Inventory
Cannabidiol
Cannabinoids
Care and treatment
chronic pain
Dog diseases
Dogs
Drug dosages
Drug therapy
Gabapentin
Health aspects
Inflammation
Nervous system
oral transmucosal administration
Osteoarthritis
Pain
Pain management
Patient outcomes
Pharmacokinetics
Pharmacology
Population studies
Quality of life
Questionnaires
Veterinary medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to evaluate the efficacy of oral transmucosal (OTM) cannabidiol (CBD), in addition to a multimodal pharmacological treatment for chronic osteoarthritis-related pain in dogs. Twenty-one dogs were randomly divided into two groups: in group CBD (n = 9), OTM CBD (2 mg kg−1 every 12 h) was included in the therapeutic protocol (anti-inflammatory drug, gabapentin, amitriptyline), while in group C (n = 12), CBD was not administered. Dogs were evaluated by owners based on the Canine Brief Pain Inventory scoring system before treatment initiation (T0), and one (T1), two (T2), four (T3) and twelve (T4) weeks thereafter. Pain Severity Score was significantly lower in CBD than in C group at T1 (p = 0.0002), T2 (p = 0.0043) and T3 (p = 0.016). Pain Interference Score was significantly lower in CBD than in C group at T1 (p = 0.0002), T2 (p = 0.0007) and T4 (p = 0.004). Quality of Life Index was significantly higher in CBD group at T1 (p = 0.003). The addition of OTM CBD showed promising results. Further pharmacokinetics and long-term studies in larger populations are needed to encourage its inclusion into a multimodal pharmacological approach for canine osteoarthritis-related pain.
ISSN:2076-2615
2076-2615
DOI:10.3390/ani10091505